Further evidence of the benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection

Abstract

[1] Cosconea S, Fontaine H, Meritet JF, Corouge M, Sogni P, Vallet-Pichard A, et al.Benefits associated with antiviral treatment in kidney allograft recipientswith chronic hepatitis B virus infection. J Hepatol 2012;57:55–60.[2] Vigano M, Colombo M, Aroldi A, Lunghi G, Manenti E, Ponticelli C, et al. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis. Antivir Ther 2005;10:709–713.[3] Aroldi A, Lampertico P, Montagnino G, Passerini P, Villa M, Campise MR, et al.Natural history of hepatitis B and C in renal allograft recipients. Transplan-tation 2005;79:1132–1136.[4] Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, et al. Impact ofhepatitis B and C virus on kidney transplantation outcome. Hepatology1999;29:257–263.[5] Ahn HJ, Kim MS, Kim YS, Kim SI, Huh KH, Ju MK, et al. Clinical outcome ofrenal transplantation in patients with positive pre-transplant hepatitis Bsurface antigen. J Med Virol 2007;79:1655–1663.[6] EASL-EORTC clinical practice guidelines: management of hepatocellularcarcinoma. J Hepatol 2012; 56:908–943.[7] European Association for the study of the L. EASL clinical practice guidelines:management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167–185.